[go: up one dir, main page]

DE10292434D2 - Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren - Google Patents

Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren

Info

Publication number
DE10292434D2
DE10292434D2 DE10292434T DE10292434T DE10292434D2 DE 10292434 D2 DE10292434 D2 DE 10292434D2 DE 10292434 T DE10292434 T DE 10292434T DE 10292434 T DE10292434 T DE 10292434T DE 10292434 D2 DE10292434 D2 DE 10292434D2
Authority
DE
Germany
Prior art keywords
airways
pharmaceuticals
peptide
treatment
diagnostic methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE10292434T
Other languages
English (en)
Inventor
Yueksel Savas
Yalcin Cetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE10292434T priority Critical patent/DE10292434D2/de
Application granted granted Critical
Publication of DE10292434D2 publication Critical patent/DE10292434D2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE10292434T 2001-06-05 2002-06-05 Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren Expired - Fee Related DE10292434D2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10292434T DE10292434D2 (de) 2001-06-05 2002-06-05 Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10127119 2001-06-05
DE10292434T DE10292434D2 (de) 2001-06-05 2002-06-05 Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
PCT/DE2002/002040 WO2002098912A2 (de) 2001-06-05 2002-06-05 Luftseitig verabreichte guanylat cyclase c liganden für atemwegserkrankungen

Publications (1)

Publication Number Publication Date
DE10292434D2 true DE10292434D2 (de) 2004-07-29

Family

ID=7687161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10292434T Expired - Fee Related DE10292434D2 (de) 2001-06-05 2002-06-05 Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren

Country Status (6)

Country Link
US (1) US20050032684A1 (de)
EP (1) EP1392729A2 (de)
AU (1) AU2002316771A1 (de)
CA (1) CA2464511A1 (de)
DE (1) DE10292434D2 (de)
WO (1) WO2002098912A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905585C (en) * 2001-03-29 2020-02-18 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT2246360E (pt) * 2003-01-28 2012-08-31 Ironwood Pharmaceuticals Inc Composições para o tratamento de desordens gastrointestinais
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
CA2619650A1 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2652677A1 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009033769A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cortistatin 14 and others as a therapeutic agent
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
EP2400975A4 (de) * 2009-02-24 2012-11-28 Univ Jefferson Verwendung von guanylylcyclase-c-agonisten zur appetitzügelung
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543628A1 (de) * 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe

Also Published As

Publication number Publication date
WO2002098912A2 (de) 2002-12-12
US20050032684A1 (en) 2005-02-10
EP1392729A2 (de) 2004-03-03
WO2002098912A3 (de) 2003-07-31
CA2464511A1 (en) 2002-12-12
AU2002316771A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
DE10292434D2 (de) Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
SE0200300D0 (sv) Diagnostic device and method
DE60231826D1 (de) Abgabevorrichtung für arzneimittel
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
CY1109212T1 (el) Φαρμακευτικες συνθεσεις για την θεραπεια του ασθμα
LTC1425001I2 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
IS9028A (is) Ný efnablanda
CY1107696T1 (el) Συνδιασμος εταβονικης λοτεπρεδνολης και dfho για την αντιμετωπιση αναπνευστικων παθησεων, αλλεργικων παθησεων, ασθματος και copd
EA200500902A1 (ru) Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
AU2003272608A8 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
DE59609123D1 (de) Austragkopf für Medien, insbesondere zur medikamentösen Behandlung des Rachens
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
DE69918961D1 (de) Verbesserte inhalationspräparate
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
ITBO20020310A0 (it) Apparato di controllo dell ' erogazione di gas medicinali , particolarmente per l ' ausilio alla respirazione
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
DE60309241D1 (de) Atemvorrichtung mit einem Vernebler
WO2001022956A3 (de) NEUE KOMBINATION VON LOTEPREDNOL UND β2-ADRENOZEPTOR-AGONISTEN
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
ATE276722T1 (de) Vorrichtung zur organisation des kombinierten gebrauchs von lokalen aerosolen und oralen medikamenten
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee